Frontiers in Pharmacology | Drugs Outcomes Research and Policies

Original Research

Published on 17 Oct 2025

Low-dose mivacurium facilitates laryngeal mask airway insertion in patients undergoing hysteroscopic surgery: a prospective, single-center, double-blind randomized controlled trial

in Drugs Outcomes Research and Policies

Yingchao Guan
Lizhen Wu
Haochen Wang
Conghui Wang
Yusong Lin
Minghong Ju
Xiaojing Cong
Wen He
Xiaodong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1700175

353 views

Original Research

Accepted on 16 Oct 2025

Ultrasound-guided Thoracic Paravertebral Block Combined with Dexmedetomidine Improves Perioperative Analgesia and Recovery in Medical Thoracoscopy: A Randomized Controlled Trial

in Drugs Outcomes Research and Policies

Jia Nie
Wei Chen
Huanhuan Ma
Liang Fang
Zhimin Deng
Yu Zhang
Hai-ying Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1684199

Original Research

Published on 15 Oct 2025

The value of pharmacist medication therapy management of capecitabine

in Drugs Outcomes Research and Policies

Jing Xue
Chengcui Huang
Xiaorui Liu
Xiaoyu Xie
Xiaoyan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1600976

946 views

Methods

Published on 14 Oct 2025

Methodological study protocol for The European Atlas of clinical trials in cancer and haematology

in Drugs Outcomes Research and Policies

Mercè Cases
Rachel Giles
Tamás Ágh
Maria Piggin
Jan Geissler
Monica Racovita
Judit Hagymásy
Lora Ruth Wogu
Ákos Józwiak
Albina Hyseni-Bocolli

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1558556

745 views

Editorial

Published on 14 Oct 2025

Editorial: Clinical pharmacist service promotes the improvement of medical quality, volume II

in Drugs Outcomes Research and Policies

Hao Li
Jianrong Zhang
Shusen Sun
Wei Luan
Zhi-Chun Gu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1714684

401 views

Original Research

Published on 14 Oct 2025

Comparison of oxcarbazepine metabolite concentrations measured by EMIT-based Siemens Viva-ProE® system and LC-MS/MS in Chinese patients

in Drugs Outcomes Research and Policies

Ming Chen
Rong-Qi Lin
Yun-Yi Mao
Ying-Bin Huang
Jun-Nan Wu
Xue-Yong Li
Xue-Mei Wu
Yu Cheng
Hong-Qiang Qiu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1697679

860 views

Original Research

Published on 14 Oct 2025

A study on a real-world data-based VTE risk prediction model for lymphoma patients

in Drugs Outcomes Research and Policies

Changli He
Yin Wang
Han Zhang
Sitian Li
Fengjiao Kang
Fengqun Cai
Lizhu Han
Qinan Yin
Gang Li
Xuewu Song

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1691271

733 views

Editorial

Published on 13 Oct 2025

Editorial: Translation of health technology reassessment and its outputs of disinvestment, de-implementation and de-adoption of drugs and medical devices in practice-what have we learned?

in Drugs Outcomes Research and Policies

Rosmin Esmail
Nora Ibargoyen-Roteta
Maximilian Otte
Iñaki Gutiérrez-Ibarluzea
Roberta Joppi
Hans-Peter Dauben

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1700196

504 views

Original Research

Accepted on 10 Oct 2025

Cost-Effectiveness of Iruplinalkib versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer Patients in China

in Drugs Outcomes Research and Policies

Wanjie Zhang
Yuqiong Lu
Zhanjing Dai
Linning Wang
Yang Zhou
Yun Lu
Feng Chang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1651463

175 views

Review

Published on 10 Oct 2025

Pharmacologic treatment of fibromyalgia: an update

in Drugs Outcomes Research and Policies

Yang Li
Yunshen Li
Shiya Wu
Meijuan Long
Xinyi Chen
Yidan Wang
Jianan Zhao
Bingheng He
Cen Chang
Juan Jiao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1651181

894 views

Review

Published on 10 Oct 2025

Digital interventions in medication adherence: a narrative review of current evidence and challenges

in Drugs Outcomes Research and Policies

Zoe Moon
Jane Walsh

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1632474

733 views

Original Research

Published on 09 Oct 2025

Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

in Drugs Outcomes Research and Policies

Yan Zhu
Cheng He
Shi-Chao Cao
Hui-Jun Li
Ru-Xue Cai
Zhao-Jun Bai
Tong-Xia Xia

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1556304

1,711 views

Original Research

Published on 09 Oct 2025

Half-dose may be equivalent to full-dose anticoagulants in preventing venous thromboembolism after primary total joint arthroplasty: a single center comparative retrospective cohort study

in Drugs Outcomes Research and Policies

Yinghao Wang
Zhixin Liao
Zongke Zhou
Haoyang Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1680985

444 views

Original Research

Published on 09 Oct 2025

Cost-effectiveness of rilertinib versus osimertinib in second-line treatment in EGFR T790M resistance mutation advanced non-small cell lung cancer in China

in Drugs Outcomes Research and Policies

Xiangcheng Li
Yun Lu
Yuqiong Lu
Mengyuan Zhou
Xiaoxi Xie
Yang Zhou
Jiaxin Qiu
Zhanjing Dai
Feng Chang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1628024

603 views

Systematic Review

Accepted on 08 Oct 2025

Different interventions in preventing sufentanil-induced cough: a systematic review and network meta-analysis

in Drugs Outcomes Research and Policies

Hao Liu
Yuewen He
Longfei Ding
Zhengze Zhang
Tong Wu
Ruogen Li
Yong Wang
Wuhua Ma

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1619920

Original Research

Accepted on 08 Oct 2025

Overcoming Barriers to Off-Patent Drug Repurposing: A Lifecycle-Based Policy Solutions

in Drugs Outcomes Research and Policies

Mario García Díaz
David Epstein
Jaime Espin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1670845

142 views